Company Overview of Edge Therapeutics, Inc.
Key Executives for Edge Therapeutics, Inc.
|Brian A. Leuthner||10 Relationships||Co-Founder, Chief Executive Officer, President and Director||51|
|R. Loch MacDonald M.D., Ph.D.||10 Relationships||Co-Founder, Chief Scientific Officer and Director||54|
|Albert N. Marchio II||No Relationships||Interim Chief Financial Officer and Chief Accounting & Administrative Officer||64|
|Daniel Brennan||38 Relationships||Chief Operating Officer||48|
|Herbert J. Faleck D.O.||No Relationships||Chief Medical Officer||63|
|View More Key Executives|
Edge Therapeutics, Inc. Board Members*
|Name||Board Relationships||Primary Company||Age|
|Sol J. Barer Ph.D.||96 Relationships||Immunomedics, Inc.||69|
|Brian A. Leuthner||10 Relationships||Edge Therapeutics, Inc.||51|
|Isaac Blech||86 Relationships||YuanMing Capital||66|
|R. Loch MacDonald M.D., Ph.D.||10 Relationships||Edge Therapeutics, Inc.||54|
|Robert S. Langer Jr., Ph.D., Sc.D.||584 Relationships||PureTech Health plc||67|
Edge Therapeutics, Inc. Executive Committees*
|Committee Name||Chairperson||Board Relationships||Members|
|Audit Committee CPA||James J. Loughlin||21 Relationships||3 Executives|
|Compensation Committee Ph.D.||Sol J. Barer||96 Relationships||1 Executives|
|Corporate Governance Committee||Isaac Blech||86 Relationships||2 Executives|
|Advisory Board Jr., Ph.D., Sc.D.||Robert S. Langer||584 Relationships||2 Executives|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
CEO COMPENSATION IN THIS INDUSTRY
|Total Short Term Compensation|
|Total Value of Options||$644.9K|
INDUSTRY EXECUTIVE CHANGES
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.